Jorge A. Garcia, MD, FACP
Advertisement
Articles by Jorge A. Garcia, MD, FACP
Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.
Advertisement
Latest Updated Articles
Management of mCRPC: Radium-223Published: May 19th 2020 | Updated:
Radium 223: Counseling Patients With mCRPCPublished: May 19th 2020 | Updated:
Case Overview: 69-Year-Old Man With Advanced CRPCPublished: May 19th 2020 | Updated:
Approaching Therapy for mCRPCPublished: May 19th 2020 | Updated:
Standard of Care for mCRPCPublished: May 19th 2020 | Updated:
Combination of Radium-223 With Other Novel Agents in mCRPCPublished: May 19th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5